Tryptamines are a group of hallucinogenic drugs whose detection in body fluids could be simplified by . Thus, they are suitable for the development of immunochemical assay kits.
Introduction
Tryptamines, a group of hallucinogenic drugs derived from tryptamine, include both natural and synthetic compounds. The best known tryptamine is dimethyltryptamine (DMT), the active compound of ayahuasca, the ritual beverage, which has traditionally been used in several South American indigenous cultures. 1 Other traditional natural tryptamines are psilocybin and psilocin, active compounds of the Psilocybe mushrooms also known as 'magic mushrooms'. Over the past few decades, lots of synthetic derivatives of tryptamine have been prepared. Their rise in popularity has been attributed to Alexander Shulgin, whose book TiHKAL (Tryptamines I have known and loved) described the synthesis and effects of many of them.
2 These synthetic tryptamines belong to the group of novel psychoactive substances (NPS), which are produced to give 'legal highs' and bypass legal restrictions. 3 Although there is widespread use of NPS on the drug scene, options for their detection, including for the detection of tryptamines, remain rather limited.
There are currently only two methods for the detection of tryptamines. The rst involves the use of specic colour tests, which are based on the reaction of specic reagents forming coloured products with indole-derived compounds. But, with so many different NPS now on the drug scene, colour tests are not reliable because of their low specicity. 4 The more commonly used second method involves the analysis of tryptamines by liquid chromatography coupled with mass spectrometry (LC-MS). 5, 6 This method is precise, capable of determining multiple targets in one run, offers low detection limits and can be used for various matrices, especially body uids. However, it is also demanding with respect to cost, sample preparation and analysis time. Furthermore, LC-MS-based techniques cannot be used in the eld.
Because of the above-mentioned disadvantages, attention has focused on immunochemical methods, such as ELISA (enzyme-linked immunosorbent assay) and LFIA (lateral ow immunosorbent assay). Antibodies for immunochemical detection are usually produced by the immunization of laboratory animals. Because tryptamines are haptens, i.e. molecules too small to be immunogenic on their own, they must be conjugated to a carrier protein prior to immunization. To do this, molecules of the target analytes are modied with short linkers containing a suitable functional group. Using bufotenine and serotonin as haptens, Skerritt et al. reported the development of an ELISA kit for the detection of DMT and 5-MeO-DMT in Phalaris plants. 7 However, this assay is limited only to these natural tryptamines and is not selective between them. Yamaguchi et al. prepared monoclonal antibodies against psilocin for identication of magic mushrooms.
8 These antibodies showed cross reactivity with DMT, but their limit of detection was relatively high. Thus far, no other immunochemical assay has been reported that targets either natural or synthetic tryptamines.
The development of LFIA kits for the detection of synthetic and other tryptamines is needed to screen potential users. To provide such a kit, we rst synthesized novel haptens carrying a short linker with a carboxyl group for the production of antibodies selective to different tryptamines. Rabbits were immunized with conjugates of these haptens with bovine serum albumin (BSA). The antibodies obtained from the immunization showed expedient sensitivity and selectivity for individual tryptamines, and, thus, appear to provide a viable basis for LFIA development. 
Materials and methods

Preparation of conjugates
Following the procedure we described previously, 10 the prepared haptens I-IV were conjugated to BSA using activated ester method. Obtained conjugates I-IV were analyzed by MALDI-TOF to determine the number of hapten molecules bound to the protein. The average values were calculated from the peak with highest intensity.
Immunisation and antiserum preparation
Four different immunisation conjugates (conjugate I-IV) were used. Antisera were produced in rabbits and obtained according to the procedure described previously.
11 Stock solutions of antisera were prepared by dissolving 1 mg of lyophilisate in 1 ml of PBS and were stored at À20 C.
Indirect competitive ELISA
ELISA microtiter plates were coated with the coating conjugates (appropriately diluted in the carbonate-bicarbonate buffer; 100 ml per well) and incubated at 4 C overnight. The following day, the plates were washed with the PBS-Tw (4 times, 350 ml per well). The suitable standard (the concentration range of 0-500 ng mL À1 in the PBS; 50 ml per well) was added into microtiter plates followed by the solution of appropriate antiserum (diluted in the PBS-0.1% BSA (w/v); 50 ml per well) and incubated at room temperature for 1 hour. Microtiter plates were washed again (4 times, 350 ml per well) and GAR-Po (diluted 1 : 10 000 in the PBS-Tw; 100 ml per well) was added and incubated at room temperature for 1 h. Aer the washing step, the TMB substrate solution was added (100 ml per well) and incubated at room temperature for 10 min. The enzyme reaction was stopped by addition of 2 mol L À1 H 2 SO 4 (50 ml per well) and the absorbance was measured at 450 nm.
Calibration standard curve
Sigmoid calibration standard curves were obtained by plotting the mean values of absorbance against the logarithm of standard concentrations through a four-parameter logistic equation as described previously. 11 The limit of detection (LOD) was dened as the concentration of an analyte corresponding to the maximum assay signal minus 3Â standard deviation (SD) in accordance with the calibration curve (the blank was calculated from 3 parallel determinations with the absence of an analyte). The IC 50 corresponded to the concentration of analyte giving 50% inhibition of the asymptotic maximum. The linear working range corresponded to the analyte concentration causing the 20-80% inhibition of the maximum assay signal.
Specicity of antibodies
To verify the ability of the antibodies to react with similar epitopes on different tryptamines, the cross-reactivity (CR) tests were performed. The percent CR (CR (%)) was calculated from IC 50 obtained from the calibration curves: (IC 50 of target drug)/ (IC 50 of tested compound) Â 100.
Results and discussion
To design the structure of haptens, DMT, 5-MeO-DMT and DiPT were selected as target analytes and their structures were modied with a short alkyl chain ended with a carboxylic group. Four different haptens were prepared, differing in a position of the linker (Fig. 1 ). Hapten I (1a) with the linker on the amino group was derived from DMT. Haptens II-IV (1b-d) with the linker in position 5 of indole ring were derived from 5-MeO-DMT (haptens II and III) and DiPT, respectively (hapten IV).
Synthesis of hapten I (1a) started from indole (2) and used a sequence of reactions developed by Speeter and Anthony to obtain N-methyltryptamine (5).
9,12 Alkylation of 5 with ethyl-4-bromobutyrate and subsequent hydrolysis of ester 6 yielded hapten I (1a) (Fig. 2) .
We used an approach based on the Fischer reaction for the synthesis of haptens II-IV (1b-d). Haptens were obtained directly from suitable arylhydrazines and amino acetals (Fig. 3 ).
Arylhydrazinium chlorides 7a,b were prepared in high yields from aniline derivatives 8a,b by diazotation and subsequent reduction of diazonium salts with SnCl 2 $2H 2 O.
13
As an acetal component of the Fischer reaction, we used N,Ndimethylamino-1,1-dimethoxybutane (9) and N,Ndiisopropylamino-1,1-dimethoxybutane (10). Compound 9 was prepared in two steps from ethyl-4-chlorobutyrate (11) (Fig. 4) .
Because the same sequence of reactions could not be used in the synthesis of acetal 10, we developed a different approach starting from succinic anhydride (13) (Fig. 5) . Reaction of 13 with diisopropylamine and subsequent reduction of acid 14 with LiAlH 4 led to the amino alcohol 15. Swern conditions were used for oxidation of 15 to aldehyde, which was immediately acetalized to obtain 10 in moderate yield. Haptens I-IV (1a-d) were conjugated with bovine serum albumin (BSA) using the methodology previously employed in our group. 10, 14 Conjugates I-IV were submitted to MALDI-TOF analysis and the number of hapten molecules was determined as follows: 13 for conjugate I, 31 for conjugate II, 28 for conjugate III and 37 for conjugate IV.
Antisera were collected by immunization of rabbits with all of prepared conjugates. 11 The indirect competitive format of ELISA was used for antiserum testing. First, checkerboard titrations were performed and suitable immunoreagent concentrations were determined when the maximum absorbance ranged from 1.2 to 1.9. Then the calibration curves with target analyte were constructed. The antibody with the highest sensitivity to the appropriate analyte was selected (on the basis of the lowest IC 50 values) for each immunisation conjugate and further tests were made. In this study, four different ELISAs (ELISA I-IV) for the detection of tryptamine-based drugs were successfully developed. Titration standard curves are shown in Fig. 6 and analytical parameters of methods are summarized in the table (Table 1) .
The specicity of obtained antibodies was evaluated with 102 new psychoactive substances and non-hallucinogenic compounds: 11 synthetic or natural tryptamines, 18 phenylethylamines, 13 piperazines, 18 synthetic cannabinoids, 27 cathinones, 16 non-hallucinogenic substance. Cross-reactivity values for tryptamines are summarized in Table 2 . Positive cross-reactivity values were obtained only for synthetic tryptamines and psilocin. No cross-reactivity was observed with other tested compounds. Our results show that synthesized haptens and immunogens are functional and that they can be used for the production of antibodies. These antibodies can be applied in the development of immunoanalytical methods for the tryptamine-based drug detection. 2-(1H-indol-3-yl)-N-methyl-2-oxoacetamide (4). Glyoxylyl chloride 3 (3.21 g, 15.5 mmol) was added in portions to an ice cold aqueous solution of methylamine (20 ml, 40 wt%) and resulting suspension was stirred at 0 C for 2 hours. The precipitate was ltered and washed with water and diethyl ether. Recrystallization of the crude product from THF/Et 2 O gave the titled compound 4 as a pale yellow solid (2.53 g, 81% (5) . The solution of amide 4 (2.00 g, 9.9 mmol) in dry THF (180 ml) was added dropwise to an ice-cold solution of LiAlH 4 (3.79 g, 100 mmol) in dry THF (180 ml) under argon atmosphere. Aer complete addition, the reaction mixture was reuxed for 7 hours. Then the mixture was cooled with an ice bath and decomposed according to Fieser workup. Precipitated salts were ltered of, washed several times with THF and the ltrate was evaporated. The residue was dissolved in dichloromethane (200 ml), washed with water (3 Â 200 ml) and brine (150 ml 
Ethyl 4-[N-[2-(1H-indol-3-yl)ethyl]-N-methyl]aminobutanoate (6).
To a mixture of N-methyltryptamine (5) (523 mg, 3.0 mmol) and NaI (450 mg, 3.0 mmol) in isopropyl alcohol (15 ml) was added DIPEA (620 mg, 835 mL, 4.8 mmol) and ethyl-4-bromobutyrate (878 mg, 645 mL, 4.5 mmol) and resulting solution was heated to 60 C overnight. Solvent was removed on rotavap. The residue was dissolved in dichloromethane (75 ml) and washed with saturated NaHCO 3 solution (75 ml), water (75 ml) and brine (75 ml 
4-[N-[2-(1H-indol-3-yl)ethyl]-N-methyl]aminobutanoic acid hydrochloride (1a, hapten I).
To a mixture of ester 5 (433 mg, 1.5 mmol) in 40% aqueous ethanol (20 ml) was added NaOH (66 mg, 1.65 mmol) and the solution was stirred at r.t. overnight. Then the solution was acidied with 1 M aqueous HCl to pH ¼ 1, evaporated and the residue was puried by reverse-phase ash chromatography (MeOH : H 2 O, gradient 5-100% MeOH) to obtain the titled compound 1a (hapten I) as a white foam (246 mg, 63%). 1 General procedure A: preparation of arylhydrazinium chlorides. A procedure from the literature 19 was modied as follows: suspension of aniline acid 8a,b (1 eq.) in concentrated hydrochloric acid (3 ml mmol À1 ) was cooled to À5 C and a solution of sodium nitrite (1.05 eq.) in water (0.5 ml mmol À1 ) was added dropwise. Aer complete addition the mixture was stirred for 1 hour at À5 C and then it was added dropwise to a solution of C. Aer addition, the reaction mixture was stirred for half hour at À78 C and then poured into ice-cold 10% hydrochloric acid (160 ml). Resulting mixture was stirred at 0 C for 1 hour, then the layers were separated and the aqueous one extracted with dichloromethane (2 Â 100 ml). Combined organic layers were washed with brine (300 ml) and dried with MgSO 4 . Aer solvent removal, the residue was dissolved in methanol (35 ml) acidied with few drops of concentrated sulfuric acid. The solution was stirred for 18 hours, diluted with dichloromethane (125 ml), washed with 10% aqueous NaHCO 3 (100 ml), water (100 ml) and brine (100 ml) and dried with MgSO4. Distillation under reduced pressure gave the titled acetal 12 as a colorless liquid (9.76 g, 78% (14) . To a solution of succinic anhydride (13) (10.07 g, 100.0 mmol) in dichloromethane (300 ml) was added diisopropyl amine (21.8 ml, 300.0 mmol) and resulting solution was stirred for 20 hours. Then the mixture was concentrated and 1 M hydrochloric acid (250 ml) was added to the residue. Aqueous layer was extracted with dichloromethane (3 Â 150 ml) and combined organic layers were dried with MgSO4. Solvent removal offered the titled compound 14 as a light brown viscous oil (16.50 g, 82%), which solidied upon standing in a fridge. 1 4-(N,N-diisopropylamino)butan-1-ol (15) . Suspension of LiAlH 4 (6.83 g, 180.0 mmol) in dry THF (300 ml) was cooled with ice bath and then the solution of amide 14 (8.05 g, 40.0 mmol) in dry THF (150 ml) was added dropwise. Aer complete addition, the reaction mixture was reuxed for 5 hours. Then it was cooled with an ice bath and decomposed according to Fieser workup. Solids were removed by ltration, washed with THF and the ltrate was evaporated. The residue was dissolved in dichloromethane (250 ml), washed with water (3 Â 200 ml) and brine (150 ml) and dried with MgSO 4 . Distillation under reduced pressure gave the titled amino alcohol 15 as a colorless liquid (4.91 g, 71% 4-(N,N-diisopropylamino)-1,1-dimethoxybutane (10). Dimethyl sulfoxide (2.56 ml, 36.0 mmol) was added dropwise to a solution of oxalyl chloride (2.57 ml, 30.0 mmol) in dry dichloromethane (60 ml) cooled to À55 C and the mixture was stirred for additional 10 minutes. Then the solution of alcohol 15 (2.60 g, 15 mmol) in dry dichloromethane (10 ml) was added and the mixture was stirred at À55 C for additional 15 minutes. Then trimethylamine (8.9 ml, 60.0 mmol) was added and the mixture was allowed to warm to r.t.
173.6; HRMS (ESI)
(1 hour). Reaction mixture was then poured into water (130 ml), phases were separated and the aqueous one extracted with dichloromethane (2 Â 100 ml). Combined organic phases were dried with MgSO 4 and evaporated. The residue was dissolved in methanol (50 ml), acidied with concentrated sulfuric acid (2.5 ml) and the mixture was stirred at r.t. for 18 hours. Then the mixture was diluted with dichloromethane (150 ml), cooled with ice bath and 20% NaOH solution was added (100 ml). Phases were separated, the aqueous one was diluted with water (50 ml) and extracted with dichloromethane (2 Â 75 ml). Combined organic phases were washed with brine (200 ml) and dried with MgSO 4 . Distillation under reduced pressure gave the titled amino acetal 10 as colorless liquid (1.74 g, 54% 
Conclusion
We successfully used haptens with novel structures to produce polyclonal antibodies against various tryptamines. The constructed ELISAs have low detection limits. Some of the antibodies show good reactivity not only with the target analytes, but also with psilocin and 5-MeO-DiPT. Although the antibodies
have not yet been characterized in complex matrices, they appear to be suitable for the development of immunochemical assay kits. In our next work, we will focus on the establishment of an ELISA for the detection of tryptamines in human body uids. We believe that the outcome of our work could lead to LFIA kits designed for the on-site testing of NPS users.
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